US2016176894A1PendingUtilityA1

Taxane and abeo-taxane analogs

51
Assignee: MCCHESNEY JAMES DPriority: Nov 27, 2013Filed: Nov 24, 2015Published: Jun 23, 2016
Est. expiryNov 27, 2033(~7.4 yrs left)· nominal 20-yr term from priority
A61K 39/3955A61K 39/395A61K 31/495A61K 45/06A61N 5/10A61K 31/53A61K 31/357C07D 493/06
51
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present application discloses new taxane analogs, intermediates and methods for producing them. The present application is also directed to pharmaceutical formulations comprising abeo-taxanes and methods of treating cancer with the abeo-taxanes.

Claims

exact text as granted — not AI-modified
1 - 40 . (canceled) 
     
     
         41 . A compound selected from the group consisting of the formulae 15a, 15a.3 and 15b.2: 
       
         
           
           
               
               
           
         
       
     
     
         42 . The compound of  claim 41 , wherein the compound is greater than 95% pure or greater than 99% pure. 
     
     
         43 . A pharmaceutical composition comprising:
 a) a therapeutically effective amount of a compound of  claim 41 , in the form of a single diastereoisomer; and   b) at least one pharmaceutically acceptable excipient, diluent or adjuvant.   
     
     
         44 . The composition of  claim 43  further comprising temozolomide and/or Avastin. 
     
     
         45 . A method for the treatment of cancer in a patient comprising administering to the patient a therapeutically effective amount of a compound of  claim 41  to a patient in need of such treatment. 
     
     
         46 . The method of  claim 45 , wherein the cancer is selected from the group consisting of leukemia, neuroblastoma, glioblastoma, cervical, colorectal, pancreatic, renal and melanoma. 
     
     
         47 . The method of  claim 45 , wherein the cancer is selected from the group consisting of lung, breast, prostate, ovarian and head and neck. 
     
     
         48 . The method of  claim 45 , wherein the compound is administered simultaneously, separately or sequentially with a chemotherapeutical agent selected from temozolomide, cisplatin, 5-flurouracil, taxotere or gemcitabine, preferably temozolomide. 
     
     
         49 . The method of  claim 45  further comprising administering radiation therapy. 
     
     
         50 . The method of  claim 45  in combination with surgical removal of a cancer.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.